Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN(TM) 3.9% Rapamycin Anhydrous Gel (QTORIN(TM) rapamycin) for the Treatment of Angiokeratomas
(NASDAQ:PVLA), Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet need With Fast Track designation, QTORIN(TM) rapamycin for angiokeratomas may be eligible for Accelerated Approval and Priority Review in the future, if applicable criteria are met Palvella plans to initiate a Phase […]